Terms: = Head and neck cancer AND SOX2, MGC2413, 6657, ENSG00000181449, MCOPS3, P48431, ANOP3 AND Treatment
106 results:
1. Identification of MUC1-C as a Target for Suppressing Progression of head and neck Squamous Cell Carcinomas.
Nakashoji A; Haratake N; Bhattacharya A; Mao W; Xu K; Wang K; Daimon T; Ozawa H; Shigeta K; Fushimi A; Yamashita N; Morimoto Y; Shimokawa M; Saito S; Egloff AM; Uppaluri R; Long MD; Kufe D
Cancer Res Commun; 2024 May; 4(5):1268-1281. PubMed ID: 38619287
[TBL] [Abstract] [Full Text] [Related]
2. sox2 promotes a cancer stem cell-like phenotype and local spreading in oral squamous cell carcinoma.
Sacco A; Battaglia AM; Santamaria G; Buffone C; Barone S; Procopio A; Lavecchia AM; Aversa I; Giorgio E; Petriaggi L; Cristofaro MG; Biamonte F; Giudice A
PLoS One; 2023; 18(12):e0293475. PubMed ID: 38096163
[TBL] [Abstract] [Full Text] [Related]
3. Super-enhancer driven sox2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma.
Liu SX; Wang C; Lin RB; Ding WY; Roy G; Wang HB; Yang T; Liu Q; Luo YL; Jin SL; Zeng MS; Zhao B; Zhong Q
EBioMedicine; 2023 Dec; 98():104870. PubMed ID: 37967508
[TBL] [Abstract] [Full Text] [Related]
4. Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC.
Wamsley NT; Wilkerson EM; Guan L; LaPak KM; Schrank TP; Holmes BJ; Sprung RW; Gilmore PE; Gerndt SP; Jackson RS; Paniello RC; Pipkorn P; Puram SV; Rich JT; Townsend RR; Zevallos JP; Zolkind P; Le QT; Goldfarb D; Major MB
Mol Cell Proteomics; 2023 Nov; 22(11):100647. PubMed ID: 37716475
[TBL] [Abstract] [Full Text] [Related]
5. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of sox2 in metastasis and radiosensitivity of nasopharyngeal carcinoma.
Hu X; Wu J; Feng Y; Ma H; Zhang E; Zhang C; Sun Q; Wang T; Ge Y; Zong D; Chen W; He X
Clin Transl Med; 2023 Sep; 13(9):e1361. PubMed ID: 37658588
[TBL] [Abstract] [Full Text] [Related]
6. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract] [Full Text] [Related]
7. Methyltransferase-like 3 facilitates the stem cell properties of esophageal cancer by upregulating patched homolog 1 via N6-methyladenosine methylation.
Liang H; Fang C; Zhang L
Am J Physiol Cell Physiol; 2023 Sep; 325(3):C770-C779. PubMed ID: 37575058
[TBL] [Abstract] [Full Text] [Related]
8. IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/sox2 pathway.
Yuan SF; Wang YM; Chan LP; Hung AC; Nguyen HDH; Chen YK; Hu SC; Lo S; Wang YY
J Transl Med; 2023 Jul; 21(1):473. PubMed ID: 37461111
[TBL] [Abstract] [Full Text] [Related]
9. GSK3β-driven sox2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma.
Kang L; Liu Y; He J; Wang Y; Xue M; Wu X; Wang Z; Zhang Y; Chu M; Li J; Wei W; Li J; Li E; Liao L; Xiao J; Zhang R; Xu L; Wong J
Oncogene; 2023 Jul; 42(30):2297-2314. PubMed ID: 37349645
[TBL] [Abstract] [Full Text] [Related]
10. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.
Zhu X; Zhao L; Doolittle WKL; Cheng SY
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
[TBL] [Abstract] [Full Text] [Related]
11. Osteogenic and Adipogenic Differentiation Potential of Oral cancer Stem Cells May Offer New treatment Modalities.
Jaksic Karisik M; Lazarevic M; Mitic D; Nikolic N; Milosevic Markovic M; Jelovac D; Milasin J
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902135
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting sox2.
Li T; Zhang G; Li W; Xiao J; Zhou Z; Tan G; Ai J
Biol Chem; 2023 Sep; 404(10):961-975. PubMed ID: 36752150
[TBL] [Abstract] [Full Text] [Related]
13. An anti-alcoholism drug, disulfiram and copper complex improves radio-resistance of tumor-initiating cells in esophageal squamous cell carcinoma.
Qian L; Murakami K; Toyozumi T; Matsumoto Y; Otsuka R; Sekino N; Endo S; Kinoshita K; Sasaki T; Matsubara H
Esophagus; 2023 Jan; 20(1):134-142. PubMed ID: 36121574
[TBL] [Abstract] [Full Text] [Related]
14. Mortality Risk factors and sox2 and mTOR expression in Patients with Esophageal cancer.
Yu G; Yuexin Y; Yin L; Yiyin Z; Mei K; Liyang Z; Lei X; Fan W
Cell Mol Biol (Noisy-le-grand); 2022 Jan; 67(4):346-357. PubMed ID: 35809269
[TBL] [Abstract] [Full Text] [Related]
15. TRPM7 via calcineurin/NFAT pathway mediates metastasis and chemotherapeutic resistance in head and neck squamous cell carcinoma.
Chen TM; Huang CM; Hsieh MS; Lin CS; Lee WH; Yeh CT; Liu SC
Aging (Albany NY); 2022 Jun; 14(12):5250-5270. PubMed ID: 35771152
[TBL] [Abstract] [Full Text] [Related]
16. HMGA2-Snai2 axis regulates tumorigenicity and stemness of head and neck squamous cell carcinoma.
Li Z; Wu X; Li J; Yu S; Ke X; Yan T; Zhu Y; Cheng J; Yang J
Exp Cell Res; 2022 Sep; 418(1):113271. PubMed ID: 35764101
[TBL] [Abstract] [Full Text] [Related]
17. Long non-coding RNA NRSN2-AS1, transcribed by sox2, promotes progression of esophageal squamous cell carcinoma by regulating the ubiquitin-degradation of PGK1.
Xu T; Yan Z; Lu J; Chen L; Li X; Li Y; Dong Z; Guo W
Clin Exp Metastasis; 2022 Oct; 39(5):757-769. PubMed ID: 35715622
[TBL] [Abstract] [Full Text] [Related]
18. Butylidenephthalide Abrogates the Snail-Induced cancer Stemness in Oral Carcinomas.
Chen PY; Chao SC; Hsieh PL; Liao YW; Chu PM; Harn HJ; Yu CC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682836
[TBL] [Abstract] [Full Text] [Related]
19. High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan.
Adnan Y; Ali SMA; Farooqui HA; Kayani HA; Idrees R; Awan MS
Int J Surg Oncol; 2022; 2022():9990489. PubMed ID: 35296132
[TBL] [Abstract] [Full Text] [Related]
20. AZD4547 targets the FGFR/Akt/sox2 axis to overcome paclitaxel resistance in head and neck cancer.
Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
[TBL] [Abstract] [Full Text] [Related]
[Next]
